Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New smart drug targets tough cancers in early trial

NCT ID NCT07090499

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 3 times

Summary

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to stick to cancer cells and kill them directly. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 540 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * Advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas * Measurable disease * ECOG Performance status 0-1 * Part 1: progression or relapse following standard treatments * Part 2: maximum of 2 prior lines of systemic therapy in the advanced setting * Resolution of acute effects of prior anticancer therapy to baseline or Grade 1 * Consent to submit required pre-treatment tumor tissue as medically feasible Exclusion criteria: * Received prior treatment with an antibody drug conjugate with a camptothecin-class payload (e.g. sacituzumab govitecan, trastuzumab deruxtecan ) * Active anorexia, nausea or vomiting, and/or signs of intestinal obstruction meeting protocol exclusion * Pulmonary disease meeting protocol exclusion * Other unacceptable abnormalities as defined by protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus Adenocarcinoma of Lung esophageal adenocarcinoma esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma exocrine pancreatic carcinoma gastroesophageal junction adenocarcinoma head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma malignant pancreatic neoplasm metastatic malignant neoplasm neoplasm non-small cell lung carcinoma pancreatic adenocarcinoma pancreatic neoplasm Squamous Cell Carcinoma of Head and Neck transitional cell carcinoma urinary bladder cancer urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced non-small cell lung cancer Advanced/metastatic solid tumors Bladder cancer Carcinoma, non-small-cell lung Carcinoma, squamous cell of head and neck Esophageal adenocarcinoma Esophageal cancer Esophageal squamous cell carcinoma Gastroesophageal junction adenocarcinoma Head and neck cancer Pancreatic adenocarcinoma Pancreatic cancer Urothelial carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    31 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Barts Cancer Centre at St. Bartholomew's Hospital; Queen Mary University of London

    NOT_YET_RECRUITING

    London, EC1A 7BE, United Kingdom

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • City of Hope National Medical Center

    RECRUITING

    Duarte, California, 91010, United States

  • City of Hope at Irvine Lennar

    RECRUITING

    Irvine, California, 92618, United States

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Dana-Farber Cancer Institute - Chestnut Hill

    RECRUITING

    Newton, Massachusetts, 02467, United States

  • Hospital Universitari Vall d'Hebron

    RECRUITING

    Barcelona, Barcelona [barcelona], 08035, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, Madrid, Comunidad de, 28041, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    RECRUITING

    Madrid, 28040, Spain

  • Hunan Cancer Hospital

    NOT_YET_RECRUITING

    Changsha, Hunan, 410013, China

  • McGill University Health Centre

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • NEXT Oncology

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Pan American Center for Oncology Trials, LLC

    RECRUITING

    Rio Piedras, 00935, Puerto Rico

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G 1Z5, Canada

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Ronald Reagan UCLA Medical Center

    NOT_YET_RECRUITING

    Los Angeles, California, 90095, United States

  • SCRI Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Santa Monica UCLA Medical Center & Orthopaedic Hospital

    NOT_YET_RECRUITING

    Santa Monica, California, 90404, United States

  • Sarah Cannon Research Institute - Pharmacy

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Smilow Cancer Hospital - Trumbull

    RECRUITING

    Trumbull, Connecticut, 06611, United States

  • Smilow Cancer Hospital - Yale New Haven Health

    RECRUITING

    New Haven, Connecticut, 06510, United States

  • Smilow Cancer Hospital Phase 1 Unit

    RECRUITING

    New Haven, Connecticut, 06511, United States

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • The University of Texas MD Anderson Cancer Center - Conroe

    RECRUITING

    Conroe, Texas, 77384, United States

  • The University of Texas, MD Anderson Cancer Center - League City

    RECRUITING

    League City, Texas, 77573, United States

  • The University of Texas, MD Anderson Cancer Center - Sugar Land

    RECRUITING

    Sugar Land, Texas, 77478, United States

  • The University of Texas, MD Anderson Cancer Center - West Houston

    RECRUITING

    Houston, Texas, 77079, United States

  • UCLA Department of Medicine-Hematology/Oncology

    NOT_YET_RECRUITING

    Los Angeles, California, 90095, United States

  • UCLA Hematology/Oncology - Santa Monica

    NOT_YET_RECRUITING

    Santa Monica, California, 90404, United States

  • University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Yale - New Haven Hospital - Yale Cancer Center

    RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.